Sicca Syndrome (Sjogren) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 97 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H2 2016, provides an overview of the Sicca Syndrome (Sjogren) (Immunology) pipeline landscape.

Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling and stiffness. Predisposing factors include age, sex and rheumatic disease.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sicca Syndrome (Sjogren) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 10, 6 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Sicca Syndrome (Sjogren) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Sjogren) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sicca Syndrome (Sjogren) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sicca Syndrome (Sjogren) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sicca Syndrome (Sjogren) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sicca Syndrome (Sjogren) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Sicca Syndrome (Sjogren) Overview 8
Therapeutics Development 9
Pipeline Products for Sicca Syndrome (Sjogren) - Overview 9
Pipeline Products for Sicca Syndrome (Sjogren) - Comparative Analysis 10
Sicca Syndrome (Sjogren) - Therapeutics under Development by Companies 11
Sicca Syndrome (Sjogren) - Therapeutics under Investigation by Universities/Institutes 13
Sicca Syndrome (Sjogren) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Sicca Syndrome (Sjogren) - Products under Development by Companies 17
Sicca Syndrome (Sjogren) - Products under Investigation by Universities/Institutes 18
Sicca Syndrome (Sjogren) - Companies Involved in Therapeutics Development 19
Akari Therapeutics Plc 19
Amgen Inc 20
Ampio Pharmaceuticals Inc 21
Atlantic Bio Sci LLC 22
Biogen Inc 23
Bristol-Myers Squibb Company 24
Eli Lilly and Company 25
F. Hoffmann-La Roche Ltd 26
GlaxoSmithKline Plc 27
MedImmune LLC 28
Novartis AG 29
Redx Pharma Plc 30
Resolve Therapeutics LLC 31
Samjin Pharmaceutical Co Ltd 32
UCB SA 33
Sicca Syndrome (Sjogren) - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
abatacept - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ABS-11 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
AMG-557 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Ampion - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
belimumab - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
belimumab + rituximab - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
BIIB-063 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
BMS-986142 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
CDZ-173 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
CFZ-533 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Coversin - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
GSK-2618960 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
IMSO-001 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
lulizumab pegol - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
LY-3090106 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
MEDI-4920 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
MEDI-7734 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
RDX-002 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
RG-7625 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
RSLV-132 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
SA-001 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
seletalisib - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
VAY-736 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
VM-200 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Sicca Syndrome (Sjogren) - Dormant Projects 93
Sicca Syndrome (Sjogren) - Discontinued Products 94
Sicca Syndrome (Sjogren) - Product Development Milestones 95
Featured News & Press Releases 95
Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren's syndrome 95
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 96
Disclaimer 97

List of Tables

Number of Products under Development for Sicca Syndrome (Sjogren), H2 2016 9
Number of Products under Development for Sicca Syndrome (Sjogren) - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Sicca Syndrome (Sjogren) - Pipeline by Akari Therapeutics Plc, H2 2016 19
Sicca Syndrome (Sjogren) - Pipeline by Amgen Inc, H2 2016 20
Sicca Syndrome (Sjogren) - Pipeline by Ampio Pharmaceuticals Inc, H2 2016 21
Sicca Syndrome (Sjogren) - Pipeline by Atlantic Bio Sci LLC, H2 2016 22
Sicca Syndrome (Sjogren) - Pipeline by Biogen Inc, H2 2016 23
Sicca Syndrome (Sjogren) - Pipeline by Bristol-Myers Squibb Company, H2 2016 24
Sicca Syndrome (Sjogren) - Pipeline by Eli Lilly and Company, H2 2016 25
Sicca Syndrome (Sjogren) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 26
Sicca Syndrome (Sjogren) - Pipeline by GlaxoSmithKline Plc, H2 2016 27
Sicca Syndrome (Sjogren) - Pipeline by MedImmune LLC, H2 2016 28
Sicca Syndrome (Sjogren) - Pipeline by Novartis AG, H2 2016 29
Sicca Syndrome (Sjogren) - Pipeline by Redx Pharma Plc, H2 2016 30
Sicca Syndrome (Sjogren) - Pipeline by Resolve Therapeutics LLC, H2 2016 31
Sicca Syndrome (Sjogren) - Pipeline by Samjin Pharmaceutical Co Ltd, H2 2016 32
Sicca Syndrome (Sjogren) - Pipeline by UCB SA, H2 2016 33
Assessment by Monotherapy Products, H2 2016 34
Assessment by Combination Products, H2 2016 35
Number of Products by Stage and Target, H2 2016 37
Number of Products by Stage and Mechanism of Action, H2 2016 39
Number of Products by Stage and Route of Administration, H2 2016 41
Number of Products by Stage and Molecule Type, H2 2016 43
Sicca Syndrome (Sjogren) - Dormant Projects, H2 2016 93
Sicca Syndrome (Sjogren) - Discontinued Products, H2 2016 94